The data from the different cohorts and registries give detailed information about treatment outcomes in daily clinical practice, both with respect to clinical and patient-reported measures. These outcomes are published in both scientific articles and general transparency reports.
For instance, recent analyses of the treat-to-target cohorts showed that more than 70% of the RA patients achieved clinical remission within one year of treatment, which is a strong improvement over usual treatment. This new treatment strategy proved to be cost-effective. Despite being initially more expensive, costs are saved in the long run.